Basal Insulin Analog — Competitive Intelligence Brief

Basal Insulin Analog (Basal Insulin Analog) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Basal insulin analog. Area: Diabetes.

marketed Basal insulin analog Insulin receptor Diabetes Small molecule

Target snapshot

Basal Insulin Analog (Basal Insulin Analog) — Eli Lilly and Company. Basal insulin analogs mimic the body's natural background insulin secretion by binding to insulin receptors and promoting glucose uptake into cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Basal Insulin Analog TARGET	Basal Insulin Analog	Eli Lilly and Company	marketed	Basal insulin analog	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Basal insulin analog class)

1. Eli Lilly and Company · 4 drugs in this class
2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
3. Montefiore Medical Center · 1 drug in this class
4. The University of Texas Health Science Center, Houston · 1 drug in this class